Zymerworks signs licensing agreement with Roche worth up to $813 million
ZYME Zymeworks BC Inc
$26.86 +3.15%
View chart & analysis → - 1Zymerworks shares rose 5.5% during Friday pre-market trading.
- 2The company announced a deal that includes a $55 million upfront payment to Zymerworks.
- 3Roche will support Phase 1a clinical trials and manage subsequent global development and commercialization.
So what's the key point?
Zymerworks signed a large technology deal with Roche. The stock price rose because the deal includes a $55 million upfront payment.
Source Investing.com · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.